Raghava R. Induru
Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Raghava R. Induru

Hematology | Oncology
945-B N. 5th St., 
Albemarle, NC 
On Staff At
Accepting New Patients
Offers Telehealth
Experienced in WT1-Related Wilms Tumor Syndromes
945-B N. 5th St., 
Albemarle, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raghava Induru is a Hematologist and an Oncologist in Albemarle, North Carolina. Dr. Induru is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Chronic Lymphocytic Leukemia (CLL). Dr. Induru is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Kasturba Medical College
Residency
Maimonides Medical Center
Specialties
Hematology
Oncology
Licenses
Hospice and Palliative Medicine in NC
Board Certifications
American Board Of Family Medicine, Hospice And Palliative Medicine
American Board Of Internal Medicine, Medical Oncology
American Board Of Internal Medicine
Fellowships
VA Medical Center, Oncology
Hospital Affiliations
Carolinas Medical Center-Northeast
Stanly Regional Medical Center
Carolinas Medical Center/behav Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Atrium Health Levine Cancer Institute, a facility of Carolinas Medical Center
945-B N. 5th St., Albemarle, NC 28001
Other Locations
Atrium Health Levine Cancer Institute
100 Medical Park Drive, NE, Concord, NC 28025

Additional Areas of Focus

Dr. Induru has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer
Leukemia
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
Enrollment Status: Terminated
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab
Study Phase: Phase 2

9 Total Publications

Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: May 31, 2024
Similar Doctors
Asim Amin
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Asim Amin
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Asim Amin
Oncology

Atrium Health Levine Cancer Institute (Medical Oncology & Immunotherapy)

1021 Morehead Medical Drive, Suite 6100, 
Charlotte, NC 
 (38.0 miles away)
980-442-5310
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Asim Amin is an Oncologist in Charlotte, North Carolina. Dr. Amin is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, and Clear Cell Sarcoma. Dr. Amin is currently accepting new patients.

Timothy Collins
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Timothy Collins
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Timothy Collins
Oncology | Hematology

Novant Health Cancer Institute - Forsyth (Medical Oncology)

1010 Bethesda Court, 
Winston Salem, NC 
 (49.6 miles away)
336-277-8800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Collins is a Hematologist and an Oncologist in Winston Salem, North Carolina. Dr. Collins is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, and Nephrectomy.

Earle F. Burgess
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Earle F. Burgess
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Earle F. Burgess
Oncology

Atrium Health Levine Cancer Institute (GI/Gastrointestinal Cancer)

1021 Morehead Medical Drive, Building 1, Suite 5300, 
Charlotte, NC 
 (38.0 miles away)
980-442-6410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Earle Burgess is an Oncologist in Charlotte, North Carolina. Dr. Burgess is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Burgess is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Induru's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 25 Advanced Conditions
    View All 118 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile